


Investor Fact Sheet

Financial key figures 2025/26


(Audited Swiss GAAP FER figures)
in thousand CHF

	2025/26	in %	2024/25	in %	Veränderung	in %
Sales of goods and services group	730 982	100.0%	748 866	100.0%	-17 885	-2.4%
Ypsomed Delivery Systems (YDS)	600 749	82.2%	501 141	66.9%	99 608	19.9%
Ypsomed Diabetes Care (YDC)	74 668	10.2%	167 302	22.3%	-92 634	-55.4%
Others	55 565	7.6%	80 423	10.7%	-24 858	-30.9%
Gross profit	314 606	43.0%	292 066	39.0%	22 540	7.7%
Operating profit group	246 074	33.7%	112 851	15.1%	133 223	118.1%
Financial income	6 128	0.8%	3 675	0.5%	2 453	66.7%
Financial expenses	-11 233	-1.5%	-12 211	-1.6%	978	-8.0%
Income taxes	-19 042	-2.6%	-16 810	-2.2%	-2 231	13.3%
Net profit	221 927	30.4%	87 504	11.7%	134 423	153.6%
Earnings per share diluted in CHF	16.31		6.41		9.90	154.5%
Earnings per share undiluted in CHF	16.30		6.41		9.89	154.2%
Operating profit	246 074	33.7%	112 851	15.1%	133 223	118.1%
Depreciation and impairment of fixed assets	59 898		64 338		-4 440	-6.9%
Amortisation and impairment of intangible assets	32 382		41 013		-8 631	-21.0%
EBITDA (Operating profit before depreciation and amortisation)	338 354	46.3%	218 201	29.1%	120 154	55.1%
Equity ratio in %	55.6%		51.1%		4.5%	
Investments in fixed assets	295 575		202 597		92 978	45.9%
Investments in intangible assets	27 528		69 672		-42 144	-60.5%
Number of employees	2 099		2 753		-654	-23.8%
Number of full-time positions	2 025		2 644		-619	-23.4%

Sales at group level



EBIT at group level



Further information on significant shareholders and shareholder groups as well as other financial figures of the Ypsomed Group can be found in the Annual Report 2025/26 and at www.ypsomed.ch.

Legal disclaimer: The information contained in this document has not been independently verified and no representation or warranty, expressed or implied, is made to, and no reliance should be placed on, the fairness, accuracy, completeness or correctness of the information or opinions contained herein. Neither Ypsomed Holding AG, its advisors or representatives, nor their respective affiliates shall have any liability whatsoever for any loss whatsoever arising from any use of this document, or its content, or otherwise arising in connection with this document. This document does not constitute, or form part of, an offer to sell or a solicitation of an offer to purchase any shares and neither it nor any part of it shall form the basis of, or be relied upon in connection with, any contract or commitment whatsoever. This document contains forward-looking statements which involve risks and uncertainties. These statements may be identified by such words as “may”, “plans”, “expects”, “believes” and similar expressions, or by their context. These statements are made on the basis of current knowledge and assumptions. Various factors could cause actual future results, performance or events to differ materially from those described in these statements. No obligation is assumed to update any forward-looking statements.

Ypsomed Holding AG // Sam Ghezlbash // Head of M&A and Investor Relations //
Brunnmattstrasse 6 // 3401 Burgdorf // Telephone +41 76 228 51 45 //
sam.ghezlbash@ypsomed.com // www.ypsomed.ch

YPSOMED
SELFCARE SOLUTIONS